Table 2 |
||||||||||||||
|
Summary of clinical characteristics of the group of untreated patients |
||||||||||||||
|
Patient number* |
P9 |
P17 |
P25 |
P32 |
P38 |
P41 |
P43 |
P45 |
P46 |
P50 |
P53 |
P61 |
P64 |
P68 |
|
Sex |
F |
F |
F |
M |
F |
F |
F |
F |
F |
F |
F |
F |
F |
F |
|
|
||||||||||||||
|
CD27+IgD+ (%) |
8 |
8 |
7 |
6 |
8 |
24 |
6 |
13 |
28 |
3 |
33 |
4 |
3 |
17 |
|
SLEDAI** score |
0 |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
SLICC*** score |
0 |
0 |
1 |
0 |
1 |
2 |
1 |
0 |
0 |
5 |
0 |
0 |
1 |
0 |
|
Disease manifestations****: |
||||||||||||||
|
Joint |
x |
x |
x |
x |
x |
x |
x |
x |
x |
x |
x |
x |
||
|
Mucocutaneous |
x |
x |
x |
x |
x |
x |
x |
x |
x |
|||||
|
CNS involvement |
x |
x |
||||||||||||
|
Renal involvement |
x |
x |
x |
|||||||||||
|
Hematologic |
x |
|||||||||||||
|
Serositis |
x |
x |
||||||||||||
|
|
||||||||||||||
|
(*) Patients' numbers are the same as in Table 1. (**) SLEDAI, Systemic Lupus Erythematosus Disease Activity Index. (***) SLICC, "Systemic Lupus International Collaborating Clinics" damage index for SLE. Except where indicated otherwise, data were obtained at the moment of the inclusion into the study. (****) The clinical manifestations that appeared throughout the course of the disease are shown. CNS: central nervous system |
||||||||||||||
|
RodrÃguez-Bayona et al. Arthritis Research & Therapy 2010 12:R108 doi:10.1186/ar3042 |
||||||||||||||
